Department of Neurophysiology, Institute of Physiology and Pathophysiology, Philipps-University Marburg, Marburg, Germany.
Department of Medical Physiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Br J Pharmacol. 2019 Aug;176(15):2708-2723. doi: 10.1111/bph.14693. Epub 2019 Jun 17.
The ether-à-go-go (Eag) K superfamily comprises closely related K 10, K 11, and K 12 subunits. K 11.1 (termed hERG in humans) gained much attention, as drug-induced inhibition of these channels is a frequent cause of sudden death in humans. The exclusive drug sensitivity of K 11.1 can be explained by central drug-binding pockets that are absent in most other channels. Currently, it is unknown whether K 12 channels are equipped with an analogous drug-binding pocket and whether drug-binding properties are conserved in all Eag superfamily members.
We analysed sensitivity of recombinant K 12.1 channels to quinine, a substituted quinoline that blocks K 10.1 and K 11.1 at low micromolar concentrations.
Quinine inhibited K 12.1, but its affinity was 10-fold lower than for K 11.1. Contrary to K 11.1, quinine inhibited K 12.1 in a largely voltage-independent manner and induced channel opening at more depolarised potentials. Low sensitivity of K 12.1 and characteristics of quinine-dependent inhibition were determined by histidine 462, as site-directed mutagenesis of this residue into the homologous tyrosine of K 11.1 conferred K 11.1-like quinine block to K 12.1(H462Y). Molecular modelling demonstrated that the low affinity of K 12.1 was determined by only weak interactions of residues in the central cavity with quinine. In contrast, more favourable interactions can explain the higher quinine sensitivity of K 12.1(H462Y) and K 11.1 channels.
The quinoline-binding "motif" is not conserved within the Eag superfamily, although the overall architecture of these channels is apparently similar. Our findings highlight functional and pharmacological diversity in this group of evolutionary-conserved channels.
醚-a-go-go(Eag)K 超家族包含密切相关的 K10、K11 和 K12 亚基。K11.1(在人类中称为 hERG)引起了广泛关注,因为这些通道的药物抑制是人类猝死的常见原因。K11.1 的独特药物敏感性可以用其中心药物结合口袋来解释,而该口袋在大多数其他通道中不存在。目前尚不清楚 K12 通道是否配备了类似的药物结合口袋,以及药物结合特性是否在所有 Eag 超家族成员中都保守。
我们分析了奎宁(一种取代的喹啉,以低微摩尔浓度阻断 K10.1 和 K11.1)对重组 K12.1 通道的敏感性。
奎宁抑制 K12.1,但亲和力比 K11.1 低 10 倍。与 K11.1 相反,奎宁以很大程度上电压不依赖的方式抑制 K12.1,并在更去极化的电位下诱导通道开放。K12.1 的低敏感性和奎宁依赖性抑制的特征由组氨酸 462 决定,因为将该残基定点突变为 K11.1 的同源酪氨酸(K12.1(H462Y))赋予 K11.1 样奎宁阻断 K12.1。分子建模表明,K12.1 的低亲和力仅由中央腔中残基与奎宁的弱相互作用决定。相比之下,更有利的相互作用可以解释 K12.1(H462Y)和 K11.1 通道更高的奎宁敏感性。
尽管这些通道的整体结构显然相似,但 Eag 超家族内并没有保守的喹啉结合“基序”。我们的研究结果突出了这组进化保守通道在功能和药理学上的多样性。